MDVL - MedAvail Holdings, Inc Stock Price, Fair Value and News

0USD0Delayed

MDVL Stock Price

View Fullscreen

MDVL RSI Chart

MDVL Valuation

EV/EBITDA

1.57

MDVL Price/Sales (Trailing)

MDVL Profitability

Operating Margin

713.95%

EBT Margin

-770.08%

Return on Equity

-199.6%

Return on Assets

-153.79%

MDVL Fundamentals

MDVL Revenue

Revenue (TTM)

1.4M

MDVL Earnings

Earnings (TTM)

-46.0M

Breaking Down MDVL Revenue

Last 7 days

-100%

Last 30 days

-100%

Last 90 days

-100%

Trailing 12 Months

-100%

How does MDVL drawdown profile look like?

MDVL Financial Health

Current Ratio

6.51

Debt/Equity

0.07

Debt/Cashflow

-20.98

MDVL Investor Care

Shares Dilution (1Y)

0.84%

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	0	0	0	0
2022	1.8M	1.6M	1.5M	1.4M
2021	16.6M	19.3M	17.9M	1.9M
2020	5.0M	7.2M	14.0M	14.0M
2019	452.0K	518.0K	802.0K	3.8M
2018	433.0K	462.0K	368.0K	360.0K
2017	282.0K	275.0K	396.0K	526.0K
2016	201.0K	243.0K	285.0K	327.0K
2015	2.3M	1.2M	0	159.0K
2014	4.6M	5.6M	0	3.3M
2013	1.2M	1.5M	2.1M	3.3M
2012	302.5K	505.6K	708.7K	911.7K
2011	0	0	0	99.5K

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of MedAvail Holdings, Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Sep 28, 2023	seabaugh ramona	sold	-1,726	5.6971	-303	chief financial officer
Sep 01, 2023	seabaugh ramona	acquired	-	-	680	chief financial officer
Mar 21, 2023	seabaugh ramona	sold	-1,009	0.307	-3,287	chief financial officer
Mar 06, 2023	doerr mark edward	sold	-22,650	0.3112	-72,785	chief executive officer
Mar 03, 2023	doerr mark edward	sold	-6,776	0.3262	-20,773	chief executive officer
Mar 03, 2023	seabaugh ramona	sold	-2,264	0.3366	-6,727	chief financial officer
Mar 01, 2023	doerr mark edward	acquired	-	-	282,259	chief executive officer
Mar 01, 2023	seabaugh ramona	acquired	-	-	28,333	chief financial officer
Jul 01, 2022	redmile group, llc	acquired	8,116,560	1.0625	7,639,120	-
Jul 01, 2022	redmile group, llc	acquired	10,000,000	1.0625	9,411,760	-

Which funds bought or sold MDVL recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 01, 2024	CONCOURSE FINANCIAL GROUP SECURITIES, INC.	sold off	-	-	-	-%
Apr 23, 2024	CIGNA INVESTMENTS INC /NEW	unchanged	-	-211,000	-	-%
Apr 23, 2024	Global Retirement Partners, LLC	sold off	-100	-26.00	-	-%
Mar 11, 2024	VANGUARD GROUP INC	reduced	-33.25	-64,178	62,999	-%
Feb 14, 2024	DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)	unchanged	-	-25,265	75,127	-%
Feb 14, 2024	Royal Bank of Canada	unchanged	-	-	-	-%
Feb 14, 2024	ADAGE CAPITAL PARTNERS GP, L.L.C.	unchanged	-	-30,200	89,800	-%
Feb 14, 2024	Redmile Group, LLC	unchanged	-	-1,141,940	3,052,080	0.11%
Feb 14, 2024	Alyeska Investment Group, L.P.	reduced	-24.66	-304,395	393,405	-%

Are Funds Buying or Selling MDVL?

Are funds buying MDVL calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own MDVL

No. of Funds

Unveiling MedAvail Holdings, Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	alyeska investment group, l.p.	5.43%	87,618	SC 13G/A
Feb 06, 2024	redmile group, llc	73.0%	2,490,137	SC 13D/A
Jun 21, 2023	redmile group, llc	73.1%	124,507,268	SC 13D/A
Jun 21, 2023	ally bridge group-wtt global life science capital partners, l.p.	34.3%	34,237,606	SC 13D/A
Mar 15, 2023	redmile group, llc	56.5%	59,194,400	SC 13D/A
Mar 15, 2023	ally bridge group-wtt global life science capital partners, l.p.	29.6%	27,419,425	SC 13D/A
Feb 14, 2023	alyeska investment group, l.p.	9.99%	8,004,500	SC 13G
Jul 06, 2022	redmile group, llc	50.7%	46,674,144	SC 13D/A
Apr 06, 2022	ally bridge group-wtt global life science capital partners, l.p.	27.1%	20,601,244	SC 13D/A
Apr 06, 2022	redmile group, llc	41.8%	32,556,498	SC 13D/A

Recent SEC filings of MedAvail Holdings, Inc

View All Filings

Date Filed	Form Type	Document
Mar 21, 2024	25-NSE	25-NSE
Feb 14, 2024	SC 13G/A	Major Ownership Report
Feb 08, 2024	8-K	Current Report
Feb 06, 2024	SC 13D/A	13D - Major Acquisition
Feb 06, 2024	4	Insider Trading
Feb 02, 2024	8-K	Current Report

Peers (Alternatives to MedAvail Holdings, Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
JNJ	359.2B	85.6B	-3.24%	-7.94%	9.34	4.19	5.68%	202.39%
MRK	323.0B	61.4B	-1.84%	8.64%	140.05	5.26	6.11%	-82.30%
AMGN	166.9B	29.5B	13.40%	34.20%	44.36	5.65	12.76%	-52.47%
PFE	157.1B	46.5B	2.20%	-27.23%	-113.14	3.37	42.59%	-114.62%
GILD	80.7B	27.1B	-8.62%	-17.50%	14.25	2.98	-0.60%	23.36%
TEVA	15.6B	15.8B	-0.99%	61.25%	-27.18	0.99	6.17%	76.47%
MID-CAP
PRGO	4.4B	4.7B	5.70%	-11.21%	-349.99	0.95	4.58%	90.97%
ALKS	4.1B	1.7B	-8.55%	-16.13%	9.38	2.36	54.01%	364.56%
BHC	2.9B	9.0B	-22.11%	32.77%	-6.3	0.32	10.01%	-27.45%
AMPH	2.0B	644.4M	1.22%	16.11%	14.84	3.17	29.14%	50.51%
SMALL-CAP
TLRY	1.6B	743.2M	-26.67%	-17.06%	-4.6	2.18	24.65%	80.36%
TXMD	22.0M	1.3M	-14.35%	-52.84%	-2.14	16.92	-98.14%	-109.18%
ACRX	17.1M	-	-	62.93%	-0.93	0.22	2882.68%	-138.52%
AGRX	2.5M	19.6M	35.71%	-93.63%	-0.17	0.13	80.00%	43.08%
ACOR	1.1M	117.6M	-94.70%	-92.62%	0	0.01	-0.79%	-283.60%

MedAvail Holdings, Inc News

Latest updates

MedAvail Holdings, Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4	2018Q3	2018Q2
Revenue	-34.7%	405,000	620,000	6,040,500	11,461,000	543,000	265,000	3,028,500	5,792,000	5,030,000	4,027,000	3,100,000	7,145,000	2,311,000	1,412,000	3,118,000	350,000	154,000	149,000	149,000	66,000	88,000
Cost Of Revenue	-37.5%	227,000	363,000	-19,121,000	10,169,000	336,000	131,000	-12,389,000	5,606,000	4,857,000	3,707,000	3,346,000	2,162,000	1,865,000	1,432,000	-	174,000	81,000	-	-	-	-
Gross Profit	-	-	-	-	-	-	-	-	186,000	173,000	320,000	-246,000	4,983,000	446,000	-20,000	611,000	176,000	73,000	88,000	52,000	7,000	26,000
Operating Expenses	-12.1%	4,632,000	5,268,000	-10,374,500	12,783,000	5,327,000	5,548,000	-11,766,000	11,211,000	10,636,000	9,971,000	27,714,000	1,045,000	921,000	985,000	1,476,000	1,087,000	1,239,000	1,051,000	1,226,000	916,000	1,060,000
S&GA Expenses	-7.6%	122,000	132,000	-4,125,500	2,126,000	55,000	100,000	-4,660,000	1,909,000	1,613,000	1,534,000	1,386,000	624,000	570,000	703,000	2,325,000	339,000	337,000	275,000	137,500	128,000	235,000
R&D Expenses	-17.6%	145,000	176,000	14,500	178,000	219,000	258,000	248,000	232,000	201,000	168,000	150,000	154,000	163,000	215,000	1,071,500	-	-	-	-	-	-
EBITDA Margin	46.5%	-6.02	-11.25	-11.48	-11.33	-10.07	-12.23	-9.61	-2.31	-1.68	-1.71	-1.75	-2.15	-4.07	-	-	-	-	-	-	-	-
Interest Expenses	-13.6%	146,000	169,000	317,000	315,000	273,000	251,000	253,000	260,000	66,000	2,000	330,000	455,000	277,000	179,000	703,000	10,000	-	-	13,000	2,000	-
Income Taxes	-	-	-	-22,000	-	24,000	-	1,000	2,000	-	-	-	-	-	-	-	-	-	-	-	-	-
Earnings Before Taxes	-Infinity%	-5,496,000	-	12,206,500	-11,806,000	-5,393,000	-13,022,000	10,939,000	-11,271,000	-10,464,000	-9,452,000	-12,096,000	-2,488,000	-6,536,000	-5,690,000	-18,462,000	-921,000	-1,175,000	-	-1,189,000	-911,000	-1,034,000
EBT Margin	41.8%	-7.70	-13.23	-13.23	-12.83	-11.40	-13.34	-10.51	-2.41	-1.79	-1.84	-1.92	-2.37	-4.40	-	-	-	-	-	-	-	-
Net Income	66.6%	-5,791,000	-17,330,000	-11,070,000	-11,806,000	-11,718,000	-13,022,000	-12,626,000	-11,273,000	-10,464,000	-9,452,000	-12,096,000	-2,488,000	-6,536,000	-5,690,000	-18,462,000	-921,000	-1,175,000	-975,000	-65,000	-911,000	-1,034,000
Net Income Margin	11.4%	-33.77	-38.12	-34.96	-32.72	-29.59	-26.55	-22.75	-2.41	-1.79	-1.84	-1.92	-2.37	-4.40	-	-	-	-	-	-	-	-
Free Cashflow	16.0%	-4,383,000	-5,217,000	-10,829,000	-11,753,000	-12,691,000	-13,643,000	-14,480,000	-11,953,000	-6,837,000	-10,090,000	-13,550,000	-5,430,000	-4,263,000	-	-	-	-	-	-	-	-

Balance Sheet

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Balance Sheet																					(In Thousands)
Description	(%) Q/Q	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4	2018Q3	2018Q2
Assets	-16.3%	29,908	35,714	33,132	49,851	52,833	27,692	38,143	52,097	61,250	59,538	69,331	3,281	4,072	3,591	18,003	3,573	4,519	5,736	4,455	4,003	4,143
Current Assets	-16.9%	27,049	32,531	28,752	39,398	40,950	15,891	30,410	42,365	54,065	53,621	63,867	2,313	3,028	2,398	14,088	2,163	2,998	4,055	2,903	2,313	2,389
Cash Equivalents	-23.6%	14,359	18,796	11,444	27,196	29,878	5,950	20,089	36,275	48,797	47,643	57,996	2,147	7,320	3,562	8,849	396	1,158	2,197	3,811	459	508
Inventory	15.7%	10,065	8,701	8,817	6,401	5,620	5,088	4,790	4,253	3,171	3,119	2,817	1,368	1,474	1,570	4,594	1,625	1,677	1,686	1,676	1,741	1,767
Net PPE	-7.2%	732	789	438	6,370	6,366	6,175	885	4,632	4,302	3,782	3,795	78.00	88.00	92.00	2,703	129	136	142	149	157	164
Liabilities	-78.2%	6,863	31,545	12,308	18,545	20,046	21,077	19,070	20,879	19,151	7,457	8,264	1,259	1,244	977	21,164	1,208	1,265	1,335	1,634	1,158	417
Current Liabilities	-19.0%	4,156	5,134	5,941	7,056	8,450	9,367	7,505	9,134	8,924	6,669	7,613	854	802	831	7,675	1,048	1,093	1,150	1,634	1,158	417
Long Term Debt	5.5%	1,506	1,428	4,798	9,751	9,679	9,608	9,538	9,466	9,414	-	-	-	-	-	12,476	-	-	-	-	-	-
LT Debt, Non Current	5.5%	1,506	1,428	4,798	9,751	9,679	9,608	9,538	9,466	9,414	-	-	-	-	-	12,476	-	-	-	-	-	-
Shareholder's Equity	452.8%	23,045	4,169	20,824	31,306	32,787	6,615	19,073	31,218	42,099	52,081	61,067	8.00	31,019	1,133	698	2,365	3,254	4,401	30,947	2,845	3,726
Retained Earnings	-2.3%	-262,827	-257,000	-239,706	-228,600	-216,800	-205,112	-192,090	-179,464	-168,191	-157,727	-148,275	-41,777	-40,962	-40,191	-121,230	-38,138	-37,217	-36,042	-35,067	-35,002	-34,091
Additional Paid-In Capital	0.2%	257,318	256,847	256,308	255,642	247,598	217,249	216,685	216,204	215,700	214,125	213,624	43,787	43,778	42,794	30,829	40,494	40,462	40,434	37,880	37,840	37,810
Shares Outstanding	0.3%	1,614	1,610	1,603	1,601	1,025	658	658	655	651	689	636	39.00	39.00	-	-	-	-	-	-	-	-
Float	-	-	-	-	-	63,600	-	-	-	399,200	-	-	-	10,500	-	-	-	13,900	-	-	-	11,300

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4	2018Q3	2018Q2
Cashflow From Operations	15.4%	-4,400	-5,200	-10,417	-11,583	-12,400	-13,300	-14,319	-11,684	-6,686	-9,830	-13,307	-5,254	-4,174	-5,899	-17,642	-769	-1,239	104	-700	-780	-
Share Based Compensation	-38.3%	381	618	555	565	612	564	257	365	323	260	145	65.00	86.00	84.00	161	22.00	28.00	243	40.00	30.00	42.00
Cashflow From Investing	-141.2%	-41.00	-17.00	-377	-171	-874	-852	-1,045	-856	-701	-712	-202	-313	-99.00	-203	-	-	-	-	-	-	-
Cashflow From Financing	-100.1%	-17.00	12,579	-4,994	9,734	37,252	-23.00	-796	-8.00	8,541	189	69,358	394	8,031	815	22,701	7.00	200	2,078	256	731	1,059

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

MDVL Income Statement

2023-06-30

Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)
$ in Thousands

3 Months Ended

6 Months Ended

Jun. 30, 2023

Jun. 30, 2022

Jun. 30, 2023

Jun. 30, 2022

Revenue:

Total revenue

$ 405

$ 543

$ 1,025

$ 808

Cost of products sold and services:

Total cost of products sold and services

227

336

590

467

Other operating expenses:

General and administrative

4,365

5,053

9,325

10,488

Selling and marketing

122

254

155

Research and development

145

219

321

477

Total operating expense

4,632

5,327

9,900

11,120

Operating loss

(4,454)

(5,120)

(9,465)

(10,779)

Loss on issuance of warrants

(10,424)

(Loss) gain from change in fair value of warrant liabilities

(896)

2,149

Interest income

Interest expense

(146)

(273)

(315)

(524)

Loss before income taxes

(5,496)

(5,393)

(18,054)

(11,302)

Income tax expense

(24)

Net loss and comprehensive loss from continued operations

(5,496)

(5,417)

(18,054)

(11,326)

Discontinued operations:

Loss from discontinued operations

(295)

(6,301)

(5,067)

(13,414)

Net loss

$ (5,791)

$ (11,718)

$ (23,121)

$ (24,740)

Basic and diluted net loss per share:

Loss from continued operations - basic (in USD per share)

^[1]

$ (3.06)

$ (3.91)

$ (10.61)

$ (11.05)

Loss from continued operations - diluted (in USD per share)

^[1]

(3.06)

(3.91)

(10.61)

(11.05)

Loss from discontinued operations - basic (in USD per share)

^[1]

(0.16)

(4.54)

(2.98)

(13.09)

Loss from discontinued operations - diluted (in USD per share)

^[1]

$ (0.16)

$ (4.54)

$ (2.98)

$ (13.09)

Weighted average shares outstanding - basic (in shares)

^[1]

1,798,245

1,387,134

1,702,360

1,024,800

Weighted average shares outstanding - diluted (in shares)

^[1]

1,798,245

1,387,134

1,702,360

1,024,800

Hardware and subscription revenue

Revenue:

Total revenue

$ 127

$ 289

$ 431

$ 454

Cost of products sold and services:

Total cost of products sold and services

131

221

376

301

Service revenue

Revenue:

Total revenue

278

254

594

354

Cost of products sold and services:

Total cost of products sold and services

$ 96

$ 115

$ 214

$ 166

[1]	Amounts have been adjusted to reflect the one-for-fifty reverse stock split effected July 31, 2023. See Note 1 and Note 14 for additional details.

MDVL Balance Sheet

2023-06-30

Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands

Jun. 30, 2023

Dec. 31, 2022

Current assets:

Cash and cash equivalents

$ 14,359

$ 11,444

Restricted cash

676

Accounts receivable

292

404

Inventories

10,065

8,817

Prepaid expenses and other current assets

711

2,569

Current assets from discontinued operations

946

4,842

Total current assets

27,049

28,752

Property, plant and equipment, net

732

438

Intangible assets, net

657

451

Right-of-use assets

701

624

Other assets

Long-term assets from discontinued operations

729

2,837

Total assets

29,908

33,132

Current liabilities:

Accounts payable

796

818

Accrued liabilities

462

552

Accrued payroll and benefits

832

1,379

Deferred revenue

346

152

Current portion of lease obligations

208

246

Current liabilities from discontinued operations

1,512

2,794

Total current liabilities

4,156

5,941

Long-term debt, net

1,506

4,798

Long-term portion of lease obligations

550

441

Long-term liabilities from discontinued operations

651

1,128

Total liabilities

6,863

12,308

Commitments and contingencies (Note 10)

Stockholders' equity:

Common shares ($0.001 par value, 300,000,000 shares authorized, 1,613,870 and 1,603,394 shares issued and outstanding at June 30, 2023 and December 31, 2022, respectively)

^[1]

Warrants

35,480

11,148

Additional paid-in-capital

257,318

256,308

Accumulated other comprehensive loss

(6,928)

Accumulated deficit

(262,827)

(239,706)

Total stockholders' equity

23,045

20,824

Total liabilities and stockholders' equity

$ 29,908

$ 33,132

[1]	Amounts have been adjusted to reflect the one-for-fifty reverse stock split effected July 31, 2023. See Note 1 and Note 14 for additional details.

About MedAvail Holdings, Inc

MedAvail Holdings, Inc., a technology-enabled retail pharmacy technology and services company, develops and commercializes self-service pharmacy, mobile application, and kiosk solutions in the United States and Canada. It offers a pharmacy technology solution, including the MedAvail MedCenter, which enables on-site pharmacy in medical clinics, retail store locations, employer sites with and without onsite clinics, and other location where onsite prescription dispensing is desired, as well as establishes an audio-visual connection to a live pharmacist enabling prescription drug dispensing to occur directly to a patient with real-time supervision by a pharmacist. The company is headquartered in Phoenix, Arizona.

CEO	Mr. Mark Doerr RPh
WEBSITE	https://medavail.com
INDUSTRY	Pharmaceuticals
EMPLOYEES	279

MedAvail Holdings, Inc Frequently Asked Questions

What is the ticker symbol for MedAvail Holdings, Inc? What does MDVL stand for in stocks?

MDVL is the stock ticker symbol of MedAvail Holdings, Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of MedAvail Holdings, Inc (MDVL)?

As of Tue Apr 16 2024, market cap of MedAvail Holdings, Inc is 0. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of MDVL stock?

You can check MDVL's fair value in chart for subscribers.

What is the fair value of MDVL stock?

You can check MDVL's fair value in chart for subscribers. The fair value of MedAvail Holdings, Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of MedAvail Holdings, Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for MDVL so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is MedAvail Holdings, Inc a good stock to buy?

The fair value guage provides a quick view whether MDVL is over valued or under valued. Whether MedAvail Holdings, Inc is cheap or expensive depends on the assumptions which impact MedAvail Holdings, Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for MDVL.

What is MedAvail Holdings, Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue Apr 16 2024, MDVL's PE ratio (Price to Earnings) is 0 and Price to Sales (PS) ratio is 0. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. MDVL PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on MedAvail Holdings, Inc's stock?

In the past 10 years, MedAvail Holdings, Inc has provided -1 (multiply by 100 for percentage) rate of return.